脂必泰联合阿托伐他汀对冠心病合并高脂血症患者hsCRP水平及IMT的影响

Influence of Zhebitai Combined with Atorvastatin on hsCRP Level and IMT in Patients with Coronary Heart Disease Complicated with Hyperlipidemia

目的探讨脂必泰联合阿托伐他汀对冠心病合并高脂血症患者超敏C反应蛋白(hsCRP)水平及颈动脉内中膜厚度(IMT)的影响。方法选择2019年1月至2021年12月本院收治的冠心病合并高脂血症患者120例,进行随机分组,各60例。对照组采用阿托伐他汀治疗,基于此,观察组加用脂必泰治疗。比较两组治疗效果、血脂水平、hsCRP、IMT以及安全性。结果观察组治疗总有效率为98.33%(59/60)高于对照组的85.00%(51/60),差异有统计学意义(P<0.05)。两组治疗前血脂、hsCRP、IMT水平比较,差异无统计学意义(P>0.05)。观察组治疗后甘油三酯(TG)(1.34±0.31)mmol/L、总胆固醇(TC)(3.14±0.43)mmol/L、低密度脂蛋白胆固醇(LDL-C)(1.76±0.38)mmol/L、hsCRP(4.03±0.49)mg/L、IMT(0.71±0.06)mm,均低于对照组(1.75±0.48)mmol/L、(4.26±0.68)mmol/L、(2.27±0.49)mmol/L、(5.96±0.71)mg/L、(0.85±0.09)mm,高密度脂蛋白胆固醇(HDL-C)(1.69±0.52)mmol/L高于对照组(1.29±0.43)mmol/L,差异有统计学意义(P<0.05)。两组治疗期间药物安全性均较好。结论与单用阿托伐他汀相比,冠心病合并高脂血症患者加用脂必泰治疗效果更佳,利于调节血脂水平,减轻炎症反应,抑制IMT增厚,具有较高的推广价值。

Objective To investigate the effect of Zibitai combined with atorvastatin on the level of high-sensitivity C-reactive protein(hsCRP)and carotid intima-media thickness(IMT)in patients with coronary heart disease complicated with hyperlipidemia.Methods A total of 120 patients with coronary heart disease complicated with hyperlipidemia admitted to our hospital from January 2019 to December 2021 were selected and randomly divided into groups,60 cases in each group.The control group was treated with atorvastatin,and based on this,the observation group was additionally treated with Zhebinol.The therapeutic effects,blood lipid levels,hsCRP,IMT and safety were compared between the two groups.Results The total effective rate of treatment in the observation group was 98.33%(59/60),which was higher than that in the control group,which was 85.00%(51/60),and the difference was statistically significant(P<0.05).There was no significant difference in the levels of blood lipids,hsCRP and IMT between the two groups before treatment(P>0.05).Triglyceride(TG)(1.34±0.31)mmol/L,total cholesterol(TC)(3.14±0.43)mmol/L,low density lipoprotein cholesterol(LDL-C)(1.76±0.38)mmol/L in observation group after treatment L,hsCRP(4.03±0.49)mg/L,IMT(0.71±0.06)mm,all lower than the control group(1.75±0.48)mmol/L,(4.26±0.68)mmol/L,(2.27±0.49)mmol/L L,(5.96±0.71)mg/L,(0.85±0.09)mm,high-density lipoprotein cholesterol(HDL-C)(1.69±0.52)mmol/L higher than the control group(1.29±0.43)mmol/L,the difference There was statistical significance(P<0.05).The drug safety was good in both groups during treatment.Conclusion Compared with atorvastatin alone,patients with coronary heart disease complicated with hyperlipidemia treated with Zibitai have better therapeutic effect,which is beneficial to regulate blood lipid level,reduce inflammatory response,and inhibit IMT thickening,which has high promotion value.